A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia;
ZRC
‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
2015 ◽
Vol 19
(11)
◽
pp. 1157-1168
◽
Keyword(s):
2010 ◽
Vol 62
(3)
◽
pp. AB2
◽
Keyword(s):
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 717.1-717
2014 ◽
Vol 15
(7-8)
◽
pp. 610-617
◽
Keyword(s):
2010 ◽
Vol 50
(10)
◽
pp. 1171-1179
◽
Keyword(s):
Keyword(s):